Immediate administration of atorvastatin decreased the serum MMP-2 level and improved the prognosis for acute heart failure

Journal of Cardiology

Volumn 59, Issue 3, 2012, Pages 374-382

  Shirakabe, Akihiro ^a   Asai, Kuniya ^a   Hata, Noritake ^a   Yokoyama, Shinya ^a   Shinada, Takuro ^a   Kobayashi, Nobuaki ^a   Tomita, Kazunori ^a   Tsurumi, Masafumi ^a   Matsushita, Masato ^a   Mizuno, Kyoichi ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Acute heart failure syndrome; Extracellular matrix; Prognosis; Treatment

Indexed keywords

ATORVASTATIN; GELATINASE A;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME BLOOD LEVEL; FEMALE; HOSPITAL READMISSION; HUMAN; LENGTH OF STAY; MALE; MATRIX METALLOPROTEINASE 2 BLOOD LEVEL; MORTALITY; PROGNOSIS;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; FEMALE; HEART FAILURE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIER ESTIMATE; MALE; MATRIX METALLOPROTEINASE 2; PROGNOSIS; PYRROLES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84860445639     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2012.01.009     Document Type: Article

References (33)

1. Yamazaki T., Lee J.D., Shimizu H., Uzui H., Ueda T. Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure. Eur J Heart Fail 2004, 6:41-45.
2. Wilson E.M., Gunasinghe H.R., Coker M.L., Sprunger P., Lee-Jackson D., Bozkurt B., Deswal A., Mann D.L., Spinale F.G. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail 2002, 8:390-398.
3. Biolo A., Fisch M., Balog J., Chao T., Schulze P.C., Ooi H., Siwik D., Colucci W.S. Episodes of acute heart failure syndrome are associated with increased levels of troponin and extracellular matrix markers. Circ Heart Fail 2010, 3:44-50.
4. Shirakabe A., Asai K., Hata N., Yokoyama S., Shinada T., Kobayashi N., Mizuno K. Clinical significance of matrix metalloproteinases in patients with acute heart failure. Int Heart J 2010, 51:404-410.
5. Nakamura M., Yamashita T., Yajima J., Oikawa Y., Ogasawara K., Sagara K., Koike A., Kirigaya H., Nagashima N., Otsuka T., Uejima T., Funada R., Matsuno S., Suzuki S., Sawada H., et al. Impact of early statin initiation on secondary prevention in Japanese patients with coronary artery disease. J Cardiol 2011, 57:172-180.
6. Miura S., Saku K. Effects of statin and lipoprotein metabolism in heart failure. J Cardiol 2010, 55:287-290.
7. Mozaffarian D., Minami E., Letterer R.A., Lawler R.L., McDonald G.B., Levy W.C. The effects of atorvastatin (10mg) on systemic inflammation in heart failure. Am J Cardiol 2005, 96:1699-1704.
8. Chang S.A., Kim Y.J., Lee H.W., Kim D.H., Kim H.K., Chang H.J., Sohn D.W., Oh B.H., Park Y.B. Effect of rosuvastatin on cardiac remodeling, function, and progression to heart failure in hypertensive heart with established left ventricular hypertrophy. Hypertension 2009, 54:591-597.
9. Trochu J.N., Mital S., Zhang X., Xu X., Ochoa M., Liao J.K., Recchia F.A., Hintze T.H. Preservation of NO production by statins in the treatment of heart failure. Cardiovasc Res 2003, 60:250-258.
10. Ramasubbu K., Estep J., White D.L., Deswal A., Mann D.L. Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008, 51:415-426.
11. Krum H., Latini R., Maggioni A.P., Anand I., Masson S., Carretta E., Ingrilli F., Pettinati G., Glazer R., Tognoni G., Cohn J. Statins and symptomatic chronic systolic heart failure: a post hoc analysis of 5010 patients enrolled in Val-HeFT. Int J Cardiol 2007, 119:48-53.
12. Khush K.K., Waters D.D., Bittner V., Deedwania P.C., Kastelein J.J., Lewis S.J., Wenger N.K. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the treating to new targets (TNT) study. Circulation 2007, 115:576-583.
13. Nakaya R., Uzui H., Shimizu H., Nakano A., Mitsuke Y., Yamazaki T., Ueda T., Lee J.D. Pravastatin suppresses the increase in matrix metalloproteinase-2 levels after acute myocardial infarction. Int J Cardiol 2005, 105:67-73.
14. Yasuda S., Miyazaki S., Kinoshita H., Nagaya N., Kanda M., Goto Y., Nonogi H. Enhanced cardiac production of matrix metalloproteinase-2 and -9 and its attenuation associated with pravastatin treatment in patients with acute myocardial infarction. Clin Sci (Lond) 2007, 112:43-49.
15. Tziakas D.N., Chalikias G.K., Parissis J.T., Hatzinikolaou E.I., Papadopoulos E.D., Tripsiannis G.A., Papadopoulou E.G., Tentes I.K., Karas S.M., Chatseras D.I. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short-term atorvastatin administration. Int J Cardiol 2004, 94:269-277.
16. Kjekshus J., Apetrei E., Barrios V., Bohm M., Cleland J.G., Cornel J.H., Dunselman P., Fonseca C., Goudev A., Grande P., Gullestad L., Hjalmarson A., Hradec J., Janosi A., Kamensky G., et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357:2248-2261.
17. Tavazzi L., Maggioni A.P., Marchioli R., Barlera S., Franzosi M.G., Latini R., Lucci D., Nicolosi G.L., Porcu M., Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1231-1239.
18. Gheorghiade M., Zannad F., Sopko G., Klein L., Pina I.L., Konstam M.A., Massie B.M., Roland E., Targum S., Collins S.P., Filippatos G., Tavazzi L. Acute heart failure syndromes: current state and framework for future research. Circulation 2005, 112:3958-3968.
19. Nieminen M.S., Harjola V.P. Definition and epidemiology of acute heart failure syndromes. Am J Cardiol 2005, 96:5G-10G.
20. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001, 103:926-933.
21. Ikeda U., Shimpo M., Ohki R., Inaba H., Takahashi M., Yamamoto K., Shimada K. Fluvastatin inhibits matrix metalloproteinase-1 expression in human vascular endothelial cells. Hypertension 2000, 36:325-329.
22. Lefer A.M., Scalia R., Lefer D.J. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res 2001, 49:281-287.
23. Aikawa M., Rabkin E., OkadaY, Voglic S.J., Clinton S.K., Brinckerhoff C.E., Sukhova G.K., Libby P. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 1998, 97:2433-2444.
24. Tousoulis D., Charakida M., Stefanadi E., Siasos G., Latsios G., Stefanadis C. Statins in heart failure. Beyond the lipid lowering effect. Int J Cardiol 2007, 115:144-150.
25. Gurjar M.V., Sharma R.V., Bhalla R.C. eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity. Arterioscler Thromb Vasc Biol 1999, 19:2871-2877.
26. Hayashidani S., Tsutsui H., Shiomi T., Suematsu N., Kinugawa S., Ide T., Wen J., Takeshita A. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002, 105:868-873.
27. Ichihara S., Noda A., Nagata K., Obata K., Xu J., Ichihara G., Oikawa S., Kawanishi S., Yamada Y., Yokota M. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. Cardiovasc Res 2006, 69:726-735.
28. Daniels L.B., Maisel A.S. Natriuretic peptides. J Am Coll Cardiol 2007, 50:2357-2368.
29. Tsutamoto T., Sakai H., Ishikawa C., Fujii M., Tanaka T., Yamamoto T., Takashima H., Ohnishi M., Wada A., Horie M. Direct comparison of transcardiac difference between brain natriuretic peptide (BNP) and N-terminal pro-BNP in patients with chronic heart failure. Eur J Heart Fail 2007, 9:667-673.
30. Gheorghiade M., Zannad F., Sopko G., Klein L., Pina I.L., Konstam M.A., Massie B.M., Roland E., Targum S., Collins S.P., Filippatos G., Tavazzi L. International Working Group on acute heart failure syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation 2005, 112:3958-3968.
31. Vrtovec B., Okrajsek R., Jan M., Starc V., Schlegel T.T., Radovancevic B. Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail 2008, 14:140-144.
32. Thambidorai S.K., Deshmukh A.R., Walters R.W., Turner P.D., Monaghan M.S., Mooss A.N., Hunter C.B., Esterbrooks D.J., Mohiuddin S.M. Impact of statin use on heart failure mortality. Int J Cardiol 2011, 147:438-443.
33. Inokubo Y., Hanada H., Ishizaka H., Fukushi T., Kamada T., Okumura K. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 2001, 141:211-217.